San Diego, CA-based Trius Therapeutics is looking to potentially represent the eighth biopharma IPO of the year if they are able to get out in the next month or so. With five companies trading (see matrix below), Trius is queued up alongside Anthera Pharma and Aldagen in an effort to make their Wall St. debut.

Taking [...]

• 623http://clsdf.com/2009/11/trius-therapeutics-5-out-3rd-in-the-ipo-queue/Trius+Therapeutics+%7C+5+Out%2C+3rd+in+the+IPO+Queue2009-11-19+01%3A03%3A05admin

GlycoMimetics (GMI), based in Gaithersburg, MD, was founded via the acquisition of assets and expertise from GlycoTech, who developed technology to identify and assay carbohydrate mimics initially through a collaboration with Ciba-Geigy, now Novartis (NYSE: NVS), and then independently. These assay capabilities were out-licensed to Wyeth, now Pfizer (NYSE: PFE). Today, GMI holds or has [...]

• 520http://clsdf.com/2009/10/glycomimetics-series-c-38m/GlycoMimetics+%7C+Series+C+%2438M2009-10-22+15%3A25%3A16admin